Hetastarch (HES)

Hetastarch, also known as hydroxyethyl starch (HES), is a synthetic colloid plasma volume expander used in equine medicine to treat conditions requiring rapid intravascular volume expansion and oncotic pressure support. This medication consists of modified starch molecules suspended in saline that remain within the vascular space longer than crystalloid fluids, providing sustained plasma volume expansion. Hetastarch represents an important therapeutic option in equine critical care for patients with hypovolemia, severe hemorrhage, or conditions causing protein loss and decreased oncotic pressure.

The mechanism of action of hetastarch involves its large molecular structure, which restricts its movement across capillary membranes into the interstitial space. When administered intravenously, hetastarch molecules exert colloidal oncotic pressure that holds water within the vascular compartment. This oncotic effect is similar to that provided by plasma proteins, particularly albumin. By maintaining or expanding intravascular volume more effectively than crystalloid fluids alone, hetastarch improves cardiac output, tissue perfusion, and oxygen delivery to tissues. The volume expansion effect typically exceeds the volume administered due to fluid redistribution from the interstitial space into the vasculature.

Hetastarch is commercially available as a 6% solution in 0.9% sodium chloride, providing a ready-to-use formulation for intravenous administration. Various hetastarch products exist with different molecular weights and substitution ratios, which affect their pharmacokinetic properties including duration of effect and metabolism. The product used in equine practice is typically human-labeled hetastarch used in an off-label capacity, as specific equine-approved colloid products are limited. Understanding the specific product being used is important as different formulations have somewhat different properties.

The safety profile of hetastarch requires careful consideration of both benefits and risks. While hetastarch provides superior and more sustained volume expansion compared to crystalloid fluids, it carries risks including effects on coagulation, potential renal effects, and the possibility of anaphylactic reactions. These concerns have led to increased scrutiny of synthetic colloid use in human medicine, and similar caution is warranted in equine applications. Hetastarch is most appropriate for specific clinical scenarios where its benefits outweigh potential risks, and veterinary supervision is essential for appropriate patient selection and monitoring.

The primary indication for hetastarch in horses is treatment of hypovolemic shock requiring rapid intravascular volume expansion. Hypovolemia in horses can result from severe hemorrhage, dehydration with intravascular volume depletion, third-spacing of fluids in conditions such as colic or peritonitis, and distributive shock associated with endotoxemia. In these situations, restoring adequate circulating volume is critical for maintaining blood pressure, cardiac output, and tissue perfusion. Hetastarch provides more effective and sustained volume expansion than crystalloid fluids alone, making it valuable in severe or refractory hypovolemia.

Hypoproteinemia with decreased colloidal oncotic pressure is another important indication for hetastarch therapy. Horses may develop hypoproteinemia through protein-losing conditions including protein-losing enteropathy, protein-losing nephropathy, severe wounds or burns, and peritonitis with protein loss into abdominal fluid. When plasma protein, particularly albumin, falls to critically low levels, fluid leaks from the vascular space into tissues, causing edema while the intravascular compartment remains depleted. Hetastarch provides temporary oncotic support while the underlying condition is addressed and natural protein production restores normal levels.

Severe hemorrhage, whether surgical or traumatic, often requires colloid support in addition to crystalloid fluids and blood products when available. While blood transfusion provides the ideal replacement for hemorrhage, hetastarch can serve as a plasma volume expander when blood products are unavailable or while they are being prepared. The colloid helps maintain intravascular volume and tissue perfusion during the critical period of hemorrhagic shock. Hetastarch does not replace lost red blood cells and their oxygen-carrying capacity, but it supports cardiovascular function.

Endotoxemia, a common and life-threatening complication of gastrointestinal disease in horses, frequently causes distributive shock with vascular leakage and relative hypovolemia. Endotoxin-induced changes in vascular permeability can make crystalloid fluid resuscitation ineffective as administered fluids rapidly exit the vascular space. Hetastarch may help maintain intravascular volume in these patients, though its use in the setting of increased vascular permeability is somewhat controversial and requires careful clinical judgment.

Perioperative use of hetastarch may be indicated for horses undergoing major surgery with significant anticipated fluid shifts or blood loss. Preoperative optimization of volume status in compromised patients and intraoperative volume replacement may include colloid support. However, the effects of hetastarch on coagulation must be considered in surgical patients where hemostasis is critical. The decision to use hetastarch perioperatively should be made by the attending veterinarian based on the specific clinical circumstances.

The dosing of hetastarch in horses requires careful clinical assessment and individualization based on the patient's hemodynamic status, underlying condition, and response to therapy. Unlike crystalloid fluids that may be administered in large volumes with relatively wide safety margins, hetastarch dosing has more specific limits due to concerns about effects on coagulation and other organ systems. Veterinary determination of appropriate dosing is essential, with ongoing assessment guiding continued therapy.

Typical dosing guidelines for hetastarch in horses range from approximately 5 to 15 milliliters per kilogram of body weight as an initial dose, with maximum daily doses generally not exceeding 20 milliliters per kilogram. For an average 500-kilogram adult horse, this translates to initial doses of roughly 2.5 to 7.5 liters, with daily maximum around 10 liters. However, these are general guidelines, and actual dosing varies considerably based on the clinical situation. Some clinicians advocate for lower doses, particularly when coagulation is a concern, while life-threatening hemorrhage may warrant higher volumes.

Treatment duration with hetastarch is typically limited due to cumulative dose concerns and cost. The goal is to provide immediate stabilization while addressing the underlying cause of volume depletion. Single-dose therapy may suffice for perioperative support, while critically ill patients may require repeated doses over 24 to 72 hours. Transition to crystalloid maintenance fluids occurs as the patient stabilizes. Total cumulative hetastarch exposure should be tracked to avoid exceeding maximum recommendations.

Administration of hetastarch requires intravenous access through an appropriately sized catheter. The 6% solution can be administered through standard IV tubing and does not require special filters. The rate of administration depends on the urgency of volume expansion; patients in shock may receive rapid boluses, while less critical situations allow for slower infusion. Response to therapy should be monitored through clinical parameters including heart rate, mucous membrane color and capillary refill time, blood pressure if measured, urine output, and improvement in mentation.

Hetastarch is often combined with crystalloid fluids as part of a comprehensive resuscitation strategy. A common approach involves administering hetastarch along with crystalloid fluids at a ratio designed to maximize intravascular expansion while limiting total colloid dose. The crystalloid component provides hydration and electrolyte replacement while the colloid component maintains oncotic pressure. Specific protocols vary among clinicians and institutions.

If planned hetastarch administration is delayed or interrupted, the clinical team should reassess the patient's hemodynamic status before resuming therapy. Volume status may have changed during the interruption, requiring protocol adjustment. Never attempt to rapidly catch up on missed colloid doses, as this increases risks of adverse effects. Documentation of total hetastarch administered is important for cumulative dose tracking.

Hetastarch is generally effective for its intended purpose of volume expansion, but it carries a side effect profile that requires careful consideration. Research in human medicine has raised concerns about synthetic colloids including hetastarch, leading to reassessment of their use. While the equine-specific data is more limited, awareness of potential adverse effects is important for appropriate patient selection and monitoring.

Common and expected effects of hetastarch administration include hemodilution of blood components proportional to the volume expansion achieved. Red blood cell counts, hemoglobin, hematocrit, and plasma protein concentrations decrease as plasma volume expands. These changes are usually mild with appropriate dosing and are outweighed by the benefits of improved perfusion. Transient decreases in coagulation factor concentrations occur similarly through dilution. Some degree of volume expansion beyond the administered volume is expected due to fluid redistribution.

Moderate side effects that warrant attention include more pronounced coagulation effects. Hetastarch can affect hemostasis through multiple mechanisms including dilution of coagulation factors, direct interference with factor VIII and von Willebrand factor, and effects on platelet function. Prolonged coagulation times, including activated partial thromboplastin time (aPTT) and potentially prothrombin time (PT), may be observed. Clinical bleeding is possible, particularly in patients with pre-existing coagulation abnormalities, those undergoing surgery, or those receiving higher cumulative doses. Monitoring of coagulation parameters is advisable in patients receiving significant hetastarch volumes.

Serious side effects associated with hetastarch include acute kidney injury, which has been documented in human critical care patients receiving hydroxyethyl starch products. The mechanism may involve uptake and accumulation of starch molecules in renal tubular cells. While equine-specific data on this effect is limited, the concern warrants caution in patients with pre-existing renal compromise or those at risk for acute kidney injury. Monitoring of renal function, including urine output and blood urea nitrogen/creatinine when possible, is prudent.

Rare side effects include anaphylactic or anaphylactoid reactions, which can occur with any colloid product. Signs may include urticaria, respiratory distress, cardiovascular collapse, and facial swelling. Patients should be monitored during initial administration, and emergency treatment capability should be available. Hetastarch molecules are not rapidly cleared from the body; they are slowly broken down by amylase and eliminated over days to weeks, with some tissue accumulation. The long-term implications of this retention in horses are not well characterized. Any unexpected clinical changes during or after hetastarch administration should prompt veterinary evaluation.

Hetastarch is contraindicated in horses with known hypersensitivity to hydroxyethyl starch products or any component of the formulation. Previous anaphylactic or severe allergic reactions to hetastarch or other synthetic colloids preclude future use. While true allergies are uncommon, they are serious when they occur and should be documented to prevent re-exposure.

Pre-existing coagulopathies represent a significant contraindication or precaution for hetastarch use. Horses with documented coagulation deficiencies, severe thrombocytopenia, or clinical evidence of bleeding disorders may have these conditions worsened by hetastarch's effects on hemostasis. The dilutional and direct effects on coagulation factors and platelets can convert subclinical coagulopathy to clinical bleeding or exacerbate existing hemorrhage. If colloid support is essential in a patient with coagulation concerns, the risks and benefits must be carefully weighed, and alternative products such as plasma may be considered.

Renal dysfunction is a relative contraindication to hetastarch based on concerns raised in human medicine regarding acute kidney injury associated with hydroxyethyl starch products. Horses with pre-existing renal disease, acute kidney injury, oliguria, or anuria may be at increased risk for worsening renal function with hetastarch administration. If hetastarch is used in these patients, renal function should be monitored closely, and alternative volume expansion strategies should be considered when possible.

Severe hypervolemia or fluid overload is a contraindication to any volume expansion therapy including hetastarch. Patients with congestive heart failure, pulmonary edema, or conditions where additional intravascular volume would be harmful should not receive colloid volume expanders. Hetastarch's prolonged intravascular residence time makes hypervolemia more difficult to reverse compared to crystalloid overload.

Certain concurrent conditions affect the risk-benefit analysis for hetastarch. Severe hyponatremia or hypernatremia should be evaluated in the context of the sodium load provided by the saline carrier solution. Patients in whom starch accumulation might be particularly problematic, though specific populations in horses are not well defined, warrant consideration. The cost of hetastarch compared to alternatives may be a practical contraindication when resources are limited and less expensive options would be adequate.

Major drug interactions with hetastarch primarily involve its effects on coagulation and potential incompatibilities with other intravenous medications. Concurrent use of anticoagulants, including heparin and low-molecular-weight heparins, may result in additive effects on hemostasis with increased bleeding risk. If both therapies are required, enhanced monitoring of coagulation status and clinical signs of bleeding is essential. Similarly, non-steroidal anti-inflammatory drugs (NSAIDs) with platelet function effects may increase bleeding risk when combined with hetastarch's coagulation effects.

Moderate interactions include those with medications affecting renal function. Aminoglycoside antibiotics such as gentamicin and amikacin are nephrotoxic and may have additive renal effects with hetastarch in susceptible patients. Other potentially nephrotoxic medications warrant similar caution. Loop diuretics such as furosemide are often used concurrently with colloids to promote diuresis while maintaining intravascular volume; this is a therapeutic combination rather than an adverse interaction, but appropriate monitoring is still required.

Physical incompatibilities exist between hetastarch and various medications. The solution should not be mixed with other drugs unless compatibility is confirmed. Incompatibilities may result in precipitation, inactivation, or other changes that affect medication efficacy or safety. When administering multiple intravenous medications to patients receiving hetastarch, separate lines or appropriate flushing between incompatible drugs is recommended. Specific compatibility information should be consulted for any drug being considered for co-administration.

Competition and drug testing considerations apply to hetastarch use in performance horses, though the context of its use (critical care for severely ill patients) generally precludes competition in the near term. Hetastarch is not a prohibited substance per se, but the conditions requiring its administration would typically preclude competition. Additionally, starch molecules persist in the body for extended periods and could theoretically be detected long after administration. Horses recovering from conditions requiring colloid therapy should be fully recovered and cleared by a veterinarian before returning to competition. Applicable regulations from FEI, USEF, racing commissions, or breed organizations should be verified if competition is anticipated.

Monitoring requirements during hetastarch therapy are essential for safe and effective use. Cardiovascular parameters including heart rate, blood pressure when available, mucous membrane color, and capillary refill time should be assessed before, during, and after administration to evaluate response to volume expansion. Urine output monitoring helps assess both volume status and renal function. Coagulation parameters, ideally including prothrombin time, activated partial thromboplastin time, and platelet count, should be evaluated at baseline and periodically during therapy, particularly with repeated dosing. Renal function monitoring through blood urea nitrogen and creatinine, when available, is prudent.

Special populations require particular caution with hetastarch. Foals receiving hetastarch need precise weight-based dosing, and their developing organ systems may be more susceptible to adverse effects. Geriatric horses are more likely to have underlying conditions including cardiac and renal disease that affect hetastarch safety. Pregnant mares require evaluation of risks to both mare and fetus, though life-threatening hypovolemia generally warrants treatment regardless of pregnancy status. Horses with pre-existing coagulation abnormalities or those undergoing or recently recovered from surgery require enhanced monitoring for bleeding complications.

Competition and performance horse considerations are generally not immediately relevant for horses sick enough to require hetastarch therapy. However, documentation of treatment is important for any horse that may eventually return to competition. The extended persistence of starch molecules in the body means that detection might theoretically be possible long after administration. Complete recovery from the underlying illness and veterinary clearance should precede any return to competition activities.

Administration precautions include ensuring appropriate intravenous access before beginning hetastarch infusion. The product should be inspected for particulates or discoloration before use; any abnormalities should prompt rejection of that container. Patients should be monitored for signs of allergic reaction during initial administration. The rate of administration should be controlled based on the patient's cardiovascular status; rapid boluses in patients with compromised cardiac function may cause harmful increases in vascular pressure. Staff should be trained to recognize signs of fluid overload and adverse reactions.

Cumulative dose tracking is important for patients receiving multiple hetastarch administrations. Total exposure should be documented to avoid exceeding maximum recommended cumulative doses. The prolonged retention of hetastarch molecules in the body means that doses from previous days still contribute to total body burden. If ongoing colloid support is required beyond typical limits, discussion of risks and potential alternatives is warranted. Long-term effects of hetastarch accumulation in horses are not well characterized, providing additional rationale for limiting cumulative exposure when clinically appropriate.

Proper storage of hetastarch maintains product sterility and stability. The solution should be stored at controlled room temperature, typically between 68°F and 77°F (20°C to 25°C). Brief exposure to temperatures up to 104°F (40°C) may be acceptable, but prolonged heat exposure should be avoided. Freezing should be avoided as it may affect the solution's properties. The product should be stored in its original packaging until ready for use to protect from light exposure and physical damage to the container.

Handling and safety practices for hetastarch focus on maintaining sterility and ensuring appropriate patient selection. Solutions should be inspected visually before use; they should be clear to slightly opalescent without visible particulates. Cloudy solutions or those with particulates should not be used. Aseptic technique is essential when accessing containers and preparing solutions for administration to prevent microbial contamination. Partially used containers should generally be discarded according to manufacturer guidelines, typically immediately after initial use due to the lack of preservatives and the high-value patient population receiving this product.

Expiration and disposal of hetastarch should follow manufacturer guidelines and institutional protocols. All containers have printed expiration dates that must be observed; expired product should not be used as stability cannot be guaranteed. Once a container is opened or punctured, the contents should be used promptly and any remainder discarded. Unused containers should be returned to inventory for future use if within expiration dating. Disposal of expired or unused hetastarch should follow pharmaceutical waste guidelines appropriate to the facility and local regulations. The relatively high cost of hetastarch provides additional incentive for proper inventory management to minimize waste from expiration.

Draft horses including Clydesdales, Percherons, Shires, and Belgians present considerations for hetastarch therapy related primarily to their large body mass. These breeds commonly weigh 1,600 to 2,200 pounds or more, requiring proportionally larger volumes of hetastarch for effective volume expansion. The cost of therapy escalates significantly with body size given the relatively high price of hetastarch compared to crystalloid fluids. Dosing must still respect maximum recommended amounts on a milliliter per kilogram basis. Draft horses have proportionally larger cardiovascular systems, and response to volume expansion should be monitored through appropriate parameters.

Light horse breeds and warmbloods represent the majority of adult horses receiving hetastarch therapy in critical care settings. Standard dosing guidelines apply to these breeds, with weights typically ranging from 900 to 1,400 pounds. These breeds are commonly involved in performance activities, and any horses recovering from conditions requiring colloid therapy should be fully recovered before returning to competition. Breed-specific conditions are generally not directly relevant to hetastarch use, though any concurrent health issues should be considered in treatment planning.

Ponies and miniature horses require careful dose calculation based on their smaller body size, typically ranging from 150 to 900 pounds. While the proportionally smaller volumes required may be less expensive than treating larger horses, precision in dosing is essential to avoid overdose. Small equines may be at increased risk for volume overload if hetastarch is administered too rapidly or in excessive amounts. Miniature horses and ponies are predisposed to metabolic conditions that may complicate critical illness but do not specifically contraindicate hetastarch use.

Breed-specific genetic conditions do not generally present specific contraindications to hetastarch use. Quarter Horses and related breeds with HYPP have potassium handling abnormalities that may be relevant to overall fluid therapy planning but do not specifically affect colloid selection. Friesians have increased susceptibility to aortic rupture, which is a consideration in cardiovascular disease but does not directly contraindicate hetastarch when volume expansion is needed. Horses of any breed with underlying cardiac conditions warrant careful monitoring during volume expansion therapy. The primary breed considerations for hetastarch therapy relate to body size affecting dosing calculations and cost rather than breed-specific pharmacological differences.

Alternative synthetic colloid products include other hydroxyethyl starch formulations with different molecular weights and substitution ratios. Tetrastarch products have lower molecular weight and different substitution patterns compared to hetastarch, with potentially different safety profiles regarding coagulation and renal effects. Pentastarch is another variant with intermediate characteristics. The specific products available vary by market and change as regulatory assessments evolve. All synthetic starches share the general mechanism of oncotic pressure support but may differ in duration of effect, metabolism, and adverse effect profiles.

Natural colloid options include plasma, which provides albumin and other proteins, coagulation factors, and immunoglobulins in addition to oncotic support. Plasma is particularly valuable when both volume expansion and coagulation support are needed, such as in hemorrhage with consumption coagulopathy. However, plasma requires compatible donors, processing time, and carries risk of transfusion reactions. Albumin solutions are used in human medicine but are rarely available for equine use due to species-specific requirements. Plasma remains the primary natural colloid option in equine practice.

Crystalloid fluids including lactated Ringer's solution and 0.9% sodium chloride are the foundation of fluid therapy and may be adequate for many situations without colloid supplementation. While crystalloids distribute throughout the extracellular space with less sustained intravascular effect than colloids, aggressive crystalloid resuscitation can achieve volume expansion in many patients. The choice between crystalloid-only versus crystalloid-plus-colloid resuscitation depends on patient condition, severity of hypovolemia, presence of oncotic deficits, and clinical judgment.

Complementary therapies support hetastarch treatment in critical patients. Oxygen supplementation improves tissue oxygenation when hemoglobin is low or perfusion is compromised. Vasopressor medications may be needed when volume expansion alone cannot maintain adequate blood pressure. Blood products including packed red blood cells address anemia and oxygen-carrying capacity deficits that colloids cannot correct. Nutritional support becomes relevant during recovery. The management of critically ill horses requiring hetastarch typically involves multiple therapeutic modalities coordinated under veterinary supervision, with hetastarch serving a specific role in oncotic pressure and volume support within a comprehensive treatment plan.